What can be more challenging than slogging in the laboratory, burning the midnight Bunsen burner, changing the methodology a few times, dealing with contaminated cell cultures and losing them, not having the transferred genes express themselves, and mining large genomics data in the terabytes?
It is communicating the science behind the research, repackaging it into plain language and dispelling the misinformation created by technology skeptics to ensure that viable science projects that help address food security and sustainable agriculture practices are commercialized, approved and reach the farms and our forks. This is no small task. Science communication is a complex field requiring special skills, training and experience. The heterogeneity of the public makes science communication both challenging and exciting. There is no cookie-cutter approach. Every audience, topic and concern must be approached differently. Each one is unique, requiring a customized communication strategy.
I have been a science communicator for 14 years and I have enjoyed every one of them, although it is not a bed of roses all the time. It requires patience and the ability to learn from our past mistakes and to perfect our techniques. Here I am sharing my agony and ecstasy.
The agony
Why is it that when scientists speak up for genetically modified (GM) crops we are immediately labeled as industry advocates and as recipients of industry money? In contrast, those who evangelize about organic products are seen as angels and saints? Yet, many of the critics of GM crops receive financial support from the organic industry and this industry has been no angel to science. Scientists who collaborate with agri-companies or receive funding from them are also demonized and their credibility trashed by critics. But, industry collaboration is not new in research at universities. The organic industry widely funds research. Why are only agribiotechnology scientists singled out?
Mahaletchumy Arujanan
Critics create myths about organic foods; instill guilt in mothers who dont feed their families with organic foods; and force consumers to pay hefty premiums in the pretext of serving more nutritious and sustainably grown foods. The claims that organic foods are more nutritious have been debunked many times. In spite of all this, GM crops and those who support them are painted as evil. For these reasons, I avoid organic foods like the plague it simply goes against my conscience.
Why is our job made so difficult while critics of GM crops have it easy? They create fear, doubts and myths. But those who embrace science take years to challenge the myths and doubts created by others. It takes years of research. Every time a doubt is created and turned into an unnecessary regulation, farmers pay the price in terms of economic losses. A good example is the failure to approve and commercialize insect resistant Bt brinjal in the Philippines (note the benefits were publicly acknowledged seven years ago but opponents successfully blocked its approval) and GM mustard in India.
It is not easy fighting ideology and hypocrisy with science. The opposition to GM crops has become a cult that no amount of science can dispel. I feel helpless when powerful tools are confiscated from farmers (see how EU Urges the G8 member states not to support GMO crops in Africaclause 72). They are deprived of technological innovations that could help them practice agriculture sustainably, prevent occupational hazards that are caused by the use of pesticides, increase their income and reduce their loss and costs.
A common accusation by critics is that GM seeds are patented by big agri-companies. But they fail to acknowledge that organic products are patented as well. Another favorite of scaremongers is that GM crops are dangerous and can even kill. Yet, since 1996 not a single GM-related health hazard has been reported. Not one. We cant however, say the same for organic produce. Read here, here and here to see the reality of safety of organic foods.
In spite of the mounting evidence on the benefits of GM crops, critics confuse the public with cooked-up evidence demonizing GM crops. For a science communicator backed by science, this is agonizing and makes my job extremely difficult.
The Ecstasy
When Malaysia was developing its Biosafety Act, I was involved in creating awareness about the need for a balanced, science-based regulatory instrument. I faced character assassination, accusations and sarcastic remarks.They were agonizing moments. But the agony turned to ecstasy when the act, and later the regulations and guidelines, became more science-based. Today, I sit in many meetings with the Ministry of Natural Resources and Environment to help implement the regulations in a balanced manner.
There have been other moments of ecstasy as well. Years ago, I waded into untested waters when I tackled issues related to Islamic principles (Shariah compliance) and GM foods. As a non-Muslim, I took a risk in handling such a sensitive topic but there were many countries that were contemplating a fatwa (decree) against GM crops, i.e. to declare GM foods and crops as haram (non-permissible). I didnt want the misinformation to spread among Muslim countries so I organized a dialogue between religious scholars and scientists.
The first meeting collapsed halfway through with many accusations hurled at me by GM opponents. I took a break from this topic for a while and analyzed my mistakes, found new credible partners and organized another high-level dialogue with top Islamic scholars from the Muslim world. It was a huge success. Here is the resolution that is used as a reference in many countries today that resulted from the discussion. Philippines became the first country after the dialogue to reverse its anti-GM rules, where initially they had a blanket decree claiming all GM foods were haram.
In 2010, I took a creative approach to educating a group that otherwise wouldnt take a second look at biotechnology fashion students, and through them a wider womens group. I engaged a university and got its fashion students to design outfits based on biotechnology themes and organized a fashion show. This was part of a bigger event called Bio Carnival with poster drawings, coloring, public speaking, debate, quizzes and spelling competitions for students, and exhibitions and hands-on sessions for the public. It was a rewarding experience when the university later introduced biotechnology as a special project for fashion students after realizing how it inspired fashion designs through its colors and unique patterns. With this approach, all the students had to search for information on biotechnology and we educated them about science and innovation.
Then there is my favorite project. I was long frustrated with the amount of space the mainstream media devoted to science issues. I tried making friends with journalists and organizing media training for scientists but it really did not effect much change. So, I decided to create my own playing field, The Petri Dish the first science newspaper in Malaysia. It is now seven years old and this year it graduated to become a digital portal to reach a wider audience.
The Petri Dish reaches all key stakeholders in Malaysia academia, researchers, policymakers, politicians (all cabinet members receive a copy), students, industry and the general public. We make it available at shopping malls and Starbucks outlets. I know a number of ministers who read it, and once a topic was fiercely debated at the cabinet meeting after being reported in The Petri Dish.
This is our initiative in bringing science to the headlines. It is aimed at creating awareness among all stakeholders on biotechnology so the public will be more receptive to emerging technologies and policymakers will be able to make informed decisions on regulations and funding. It also encourages young people to pursue STEM education and careers. Every time, I receive positive feedback on Petri Dish, I feel a rush of ecstasy. It is a struggle to sustain a science newspaper but the feeling of inspiring people about science is rewarding.
Another area I enjoy is talking to students both at schools and universities. These are uncorrupted minds and they are receptive to information backed by science when it is presented by a credible person. Every year, I reach out to more than 2000 students who are inspired by science and believe it offers solutions to many global problems.
The biggest lesson I have learned is that we need to build trust with our audiences before we start communicating with them: Connecting first and then communicating.
I believe the agony and ecstasy will continue, with exciting new developments in synthetic biology, gene editing and gene drives.
Mahaletchumy Arujanan is the Executive Director of Malaysian Biotechnology Information Centre (MABIC) and Editor-in-Chief of The Petri Dish the first science newspaper in Malaysia. She is also an Adjunct Lecturer at Monash University Malaysia. She has a degree in Biochemistry and Microbiology from Universiti Putra Malaysia, Masters in Biotechnology and PhD in science communication from the University of Malaya. She is an active science communicator who addresses policies, regulations, ethics, religions, STEM and other areas pertinent to biotechnology development. You can follow her onFacebook and Twitter @maha_mabic.
For more background on the Genetic Literacy Project, read GLP on Wikipedia
Follow this link:
March for Science: Agony and ecstasy of a Malaysian agricultural biotechnology science communicator - Genetic Literacy Project
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022